Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
Adenovirus gene therapy for intraperitoneal (IP) cancer is limited in clinical trials by inefficient tumor cell transduction and development of peritoneal adhesions. We have shown previously that normal virus tropism can be ablated by physically shielding the virus surface with reactive hydrophilic...
主要な著者: | Morrison, J, Briggs, S, Green, N, Fisher, K, Subr, V, Ulbrich, K, Kehoe, S, Seymour, L |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2008
|
類似資料
-
Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
著者:: Morrison, J, 等
出版事項: (2009) -
Retargeting adenovirus gene therapy via the epidermal growth factor receptor
著者:: Morrison, J, 等
出版事項: (2006) -
Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
著者:: Green, N, 等
出版事項: (2008) -
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
著者:: Fisher, K, 等
出版事項: (2001) -
E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.
著者:: Bachtarzi, H, 等
出版事項: (2011)